导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.02% | 2413/4773 |
| 近一周 | -2.46% | 3905/5465 |
| 近一月 | -6.79% | 4325/5421 |
| 近一季 | -13.53% | 4159/5231 |
| 近半年 | -2.40% | 2117/4920 |
| 近一年 | 2.37% | 2285/4394 |
| 近两年 | 60.01% | 1239/2954 |
| 近三年 | 31.83% | 1020/2253 |
| 成立以来 | 78.13% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.55% 2359/4961 |
20.70% 1210/5312 |
- - |
- - |
| 2025 | 26.22% 1645/4813 |
-0.67% 2345/3635 |
-0.51% 2945/4076 |
30.13% 1197/4524 |
-1.86% 3028/4813 |
| 2024 | 12.90% 1202/3463 |
0.38% 988/2808 |
-3.30% 1339/3014 |
19.92% 787/3129 |
-3.01% 2232/3463 |
| 2023 | -15.32% 1645/2656 |
4.38% 968/2280 |
-6.06% 1584/2385 |
-7.29% 1552/2515 |
-6.84% 1941/2655 |
| 2022 | -24.07% 1187/2207 |
-18.12% 1301/1919 |
9.00% 309/2016 |
-16.34% 1444/2113 |
1.70% 1176/2208 |
| 2021 | 0.36% 715/1822 |
-4.49% 866/1255 |
10.41% 464/1330 |
-7.59% 1065/1466 |
2.99% 487/1822 |
| 2020 | 48.57% 181/1250 |
-5.40% 416/1028 |
21.33% 236/1067 |
10.24% 572/1164 |
17.42% 126/1184 |
| 2019 | 53.30% 83/1092 |
36.38% 86/754 |
-3.05% 372/804 |
4.58% 192/850 |
10.87% 91/918 |
| 2018 | -32.17% 520/834 |
- - |
- - |
- - |
-13.78% 553/691 |
| 2017 | 25.68% 113/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.72% 326/605 |
- - |
- - |
- - |
- - |
| 2015 | 21.79% 109/575 |
- - |
- - |
- - |
- - |
| 2014 | 33.01% 154/237 |
- - |
- - |
- - |
- - |
| 2013 | -3.19% 75/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.39% 97/140 |
- - |
- - |
- - |
- - |
| 2011 | -28.96% 86/102 |
- - |
- - |
- - |
- - |
| 2010 | -0.50% 9/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达深证100ETF联接A VS. 长安沪深300非周期A(740101) |